Identifying responders to trastuzumab therapy in breast cancer

Future Oncology

Volumn 7, Issue 6, 2011, Pages 767-773

  Brügmann, Anja ^a   Sorensen, Boe S ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

breast cancer; EGF family; HER2; responders; trastuzumab

Indexed keywords

BIOTIN; CHROMOGENIC SUBSTRATE; DIMER; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; LIGAND; METALLOPROTEINASE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; PROTEINASE; RADIOISOTOPE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

BIOTINYLATION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SIZE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CENTROMERE; DNA DETERMINATION; DRUG ACCUMULATION; DRUG BINDING SITE; DRUG CONJUGATION; DRUG DISTRIBUTION; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME PHOSPHORYLATION; EXTRACELLULAR SPACE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION; MENOPAUSE; METHYLATION; MUTATION; NATURAL KILLER CELL; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; RADIOIMMUNOTHERAPY; REPRODUCIBILITY; REVIEW; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING; TREATMENT RESPONSE; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 79959473659     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.44     Document Type: Review

References (51)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987) (Pubitemid 17231334)
2. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27, 1323-1333 (2009)
3. Nahta R, Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett. 232, 123-138 (2006) (Pubitemid 43170962)
4. Baselga J, Tripathy D, Mendelsohn J et al.: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737-744 (1996)
5. Cobleigh MA, Vogel CL, Tripathy D et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic dizease. J. Clin. Oncol. 17, 2639-2648 (1999) (Pubitemid 29415219)
6. Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002) (Pubitemid 34111379)
7. Viale G, Ghioni M, Mastropasqua MG: Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies. Curr. Opin. Oncol. 22, 541-546 (2010)
8. Cuadros M, Villegas R: Systematic review of HER2 breast cancer testing. Appl. Immunohistochem. Mol. Morphol. 17, 1-7 (2009)
9. Wolff AC, Hammond ME, Schwartz JN et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145 (2007) (Pubitemid 350003059)
10. Mass RD, Press MF, Anderson S et al.: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer 6, 240-246 (2005) (Pubitemid 47050800)
11. Gruver AM, Peerwani Z, Tubbs RR: Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J. Clin. Pathol. 63, 210-219 (2010)
12. Brügmann A, Lelkaitis G, Nielsen S et al.: Testing HER2 in Breast Cancer: a Comparative Study on BRISH, FISH, and IHC. Appl. Immunohistochem. Mol. Morphol. 19, 203-211 (2011)
13. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320-368 (2009)
14. Scaltriti M, Rojo F, Ocana A et al.: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Inst. 99, 628-638 (2007) (Pubitemid 47073544)
15. Mitra D, Brumlik MJ, Okamgba SU et al.: An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol. Cancer Ther. 8, 2152-2162 (2009)
16. Witton CJ: Structure of HER receptors and intracellular localisation of downstream effector elements gives insight into mechanism of tumour growth promotion. Breast Cancer Res. 5, 206-207 (2003) (Pubitemid 36818162)
17. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG: Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 6, R246-R251 (2004)
18. Suo Z, Risberg B, Kalsson MG et al.: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J. Pathol. 196, 17-25 (2002)
19. Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E: The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br. J. Cancer 94, 1703-1709 (2006) (Pubitemid 43924936)
20. Sassen A, Diermeier-Daucher S, Sieben M et al.: Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res. 11, R50 (2009)
21. Valabrega G, Montemurro F, Sarotto I et al.: TGFa expression impairs trastuzumab-induced HER2 downregulation. Oncogene 24, 3002-3010 (2005) (Pubitemid 40675531)
22. Wang SE, Xiang B, Guix M et al.: Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/AKT in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol. Cell Biol. 28, 5605-5620 (2008)
23. Ritter CA, Perez-Torres M, Rinehart C et al.: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 13, 4909-4919 (2007) (Pubitemid 47294799)
24. Lu Y, Zi X, Pollak M: Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer 108, 334-341 (2004) (Pubitemid 37549597)
25. Shattuck DL, Miller JK, Carraway KL III, Sweeney C: Met receptor contributes to trastuzumab resistance of HER2- overexpressing breast cancer cells. Cancer Res. 68, 1471-1477 (2008) (Pubitemid 351346855)
26. Perez-Tenorio G, Alkhori L, Olsson B et al.: PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 13, 3577-3584 (2007) (Pubitemid 46955118)
27. Berns K, Horlings HM, Hennessy BT et al.: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402 (2007) (Pubitemid 47539306)
28. Nagata Y, Lan KH, Zhou X et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004) (Pubitemid 39485684)
29. Esteva FJ, Guo H, Zhang S et al.: PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am. J. Pathol. 177, 1647-1656 (2010)
30. Musolino A, Naldi N, Bortesi B et al.: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26, 1789-1796 (2008)
31. Yuan CX, Lasut AL, Wynn R et al.: Purification of HER-2 extracellular domain and identification of its cleavage site. Protein Expr. Purif. 29, 217-222 (2003) (Pubitemid 36720252)
32. Leary AF, Hanna WM, van de Vijver MJ et al.: Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J. Clin. Oncol. 27, 1694-1705 (2009)
33. Mazouni C, Hall A, Broglio K et al.: Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 109, 496-501 (2007) (Pubitemid 46190957)
34. Kostler WJ, Steger GG, Soleiman A et al.: Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res. 24, 1127-1130 (2004) (Pubitemid 38624950)
35. Molina R, Filella X, Lejarcegui JA et al.: Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol. 24, 156-164 (2003) (Pubitemid 37465053)
36. Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H: Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int. J. Cancer 89, 329-336 (2000) (Pubitemid 30620285)
37. Krainer M, Brodowicz T, Zeillinger R et al.: Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 54, 475-481 (1997) (Pubitemid 27470258)
38. Kostler WJ, Schwab B, Singer CF et al.: Monitoring of serum HER-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin. Cancer Res. 10, 1618-1624 (2004) (Pubitemid 38435551)
39. Sorensen PD, Jakobsen EH, Langkjer ST et al.: Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin. Chem. Lab. Med. 47, 1117-1123 (2009)
40. Sozzi G, Roz L, Conte D et al.: Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am. J. Respir. Crit. Care Med. 179, 69-74 (2009)
41. Maheswaran S, Sequist LV, Nagrath S et al.: Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377 (2008)
42. Sorensen BS, Mortensen LS, Andersen J, Nexo E: Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer. Anticancer Res. 30, 2463-2468 (2010)
43. Bussolati G, Montemurro F, Righi L, Donadio M, Aglietta M, Sapino A: A modified trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. Br. J. Cancer 92, 1261-1267 (2005) (Pubitemid 40604401)
44. Sapino A, Montemurro F, Marchio C et al.: Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. Ann. Oncol. 18, 1963-1968 (2007) (Pubitemid 350286232)
45. Sharkey RM, Goldenberg DM: Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46(Suppl. 1), S115-S127 (2005)
46. Rasaneh S, Rajabi H, Babaei MH, Daha FJ: 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl. Med. Biol. 37, 949-955 (2010)
47. Luo TY, Tang IC, Wu YL et al.: Evaluating the potential of 188Re- SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment. Nucl. Med. Biol. 36, 81-88 (2009)
48. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004) (Pubitemid 38637993)
49. Paez JG, Janne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004) (Pubitemid 38720929)
50. Nagrath S, Sequist LV, Maheswaran S et al.: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235-1239 (2007)
51. Riethdorf S, Pantel K: Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Ann. NY Acad. Sci. 1210, 66-77 (2010)